Pharmaceuticals

Ultomiris Market 2026 expanding through rare disease therapy advancements and longer dosing cycles

March 27, 2026March 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Ultomiris Market Projected To Become By 2030 Based On Its 2026 Valuation?

The historical growth was driven by improved identification of rare autoimmune diseases, progress in monoclonal antibody engineering, a broadening of biologics reimbursement systems, heightened clinician understanding of complement disorders, and the presence of hospital infusion infrastructure.

Growth throughout the forecast period is anticipated due to increasing investments in the development of drugs for rare diseases, a rising adoption of subcutaneous drug formulations, the expansion of home-based infusion care services, a growing emphasis on long-term disease management, and an increasing demand for therapies that reduce treatment burden. Major trends foreseen for this period include the rising adoption of long-acting complement inhibitors, a growing preference for extended dosing intervals, the increasing use of targeted autoimmune therapies, the expansion of rare disease treatment programs, and an enhanced focus on patient-centric infusion models.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20415&type=smp

What Primary Drivers Are Shaping The Development Of The Ultomiris Market?

The ultomiris market is anticipated to experience growth driven by the increasing occurrence of autoimmune conditions. Autoimmune conditions are disorders where the immune system mistakenly attacks and harms the body’s healthy cells and tissues. This rise in prevalence can be attributed to both environmental factors, such as contact with pollutants and chemicals, and enhanced diagnostic capabilities, which have led to more individuals being identified and treated for these diseases. Ultomiris is used to treat autoimmune conditions like Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) by inhibiting complement protein C5, thereby reducing immune system assaults on the body. For example, in February 2024, data from Arthritis Australia, an Australia-based non-profit organization, projected that in 2025, approximately 212,136 males and 362,137 females would have rheumatoid arthritis (RA), with these numbers expected to increase by 2040 to roughly 280,040 males and 479,828 females. Thus, the escalating prevalence of autoimmune conditions is acting as a catalyst for the expansion of the ultomiris market.

What Segment Groups Are Identified Within The Ultomiris Market?

The ultomiris market covered in this report is segmented –

1) By Indication: Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Neuromyelitis Optica Spectrum Disorder (NMOSD)

2) By Formulation: Intravenous Solution, Subcutaneous Formulation

3) By Distribution Channel: Hospital And Clinics, Retail And Specialty Pharmacies

4) By End User: Adult Patients, Pediatric Patients

What Trends Are Advancing Progress In The Ultomiris Market?

A significant development in the ultomiris market centers on drug approvals from regulatory bodies aimed at expanding its therapeutic uses and market reach. Drug approval represents the process by which regulatory authorities assess and authorize a new medication for commercialization and consumption, verifying its safety, efficacy, and quality based on evidence from clinical trials. For example, in March 2024, AstraZeneca, a pharmaceutical company based in the UK, obtained Food and Drug Administration (FDA) approval for ULTOMIRIS (ravulizumab-cwvz) for treating adults with neuromyelitis optica spectrum disorder (NMOSD) who test positive for the anti-aquaporin-4 (AQP4) antibody. This approval is particularly important as ULTOMIRIS stands as the first long-acting C5 complement inhibitor for NMOSD, having shown a 98.6% reduction in relapse risk during clinical trials. ULTOMIRIS operates by inhibiting the complement system, thereby helping to prevent immune attacks on the central nervous system. However, it carries associated risks, including serious meningococcal infections and common adverse effects such as headache and urinary tract infections.

Which Companies Hold Significant Positions In The Ultomiris Market?

Major companies operating in the ultomiris market are AstraZeneca Plc.

Read the full ultomiris market report here:

https://www.thebusinessresearchcompany.com/report/ultomiris-global-market-report

How Does The Ultomiris Market Perform Across Major Global Regions?

North America was the largest region in the ultomiris market in 2025. The regions covered in the ultomiris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Ultomiris Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20415&type=smp

Browse Through More Reports Similar to the Global Ultomiris Market 2026, By The Business Research Company

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Pressure Ulcers Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/pressure-ulcers-treatment-global-market-report

Gastric Ulcers Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-ulcers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795